GPRC6A and metabolic dysfunction-associated steatotic liver disease: A murine circulating pentadecapeptide derived from pre-osteocalcin, binding to GPRC6A, could also alleviate the symptoms of NAFLD by inhibiting lipid absorption and insulin resistance (36).